Abstract: Provided herein are bioactivated polymer/extracellular matrix (ECM) composites and methods of preparation and use thereof. In particular, heparinized cysteine-polymer/ECM composites, and methods of preparation and use thereof, are provided. In some embodiments, provided herein are compositions comprising a composite of: (a) extracellular matrix (ECM), and (b) a polyester covalently linked to a bioactive agent. In some embodiments, the composite is a homogeneous composite. In some embodiments, the ECM is decellularized ECM. In some embodiments, the ECM is not substantially crosslinked.

Abstract: Chimeric polyvalent recombinant proteins for use as vaccines and diagnostics for Lyme disease (e.g. in canines and humans) are provided. The chimeric proteins comprise epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types and/or OspE types. The OspC types may be associated with mammalian Borrelia infections.

Abstract: The invention provides antibodies or an antigen-binding portion thereof, which recognize the human Frizzled 7 receptor. Further, the invention provides methods of using these antibodies for the treatment cancer in a subject.

Abstract: Variant peptides of calcitonin gene-related peptide alpha (?CGRP), calcitonin gene-related peptide beta (?CGRP), and adrenomedullin (AM) are disclosed, wherein the variant peptides have high binding affinity and agonistic or antagonistic activity for at least one receptor complex of CLR:RAMP1, CLR:RAMP2, and CLR:RAMP3. Also disclosed are methods of use of the variant peptides in therapeutic treatments.

Abstract: Three-layer full-color dynamic electronic paper, comprising a substrate, a controller, a first EWOD display layer, a second EWOD display layer and a third EWOD display layer, wherein each of the first, second and third EWOD display layer is comprised of an upper transparent electrode plate, a hydrophobic insulating layer, pixel walls, colored ink, colorless liquid, a lower transparent electrode plate, an encapsulation adhesive, and a driving chip connected to the upper transparent electrode plate and the lower transparent electrode plate respectively; the lower transparent electrode plate of the third EWOD display layer is located above the substrate; the colored ink filled in the first, second and third EWOD display layer is cyan ink, magenta ink and yellow ink, respectively; and, the controller controls voltage waveforms of the three driving chips according to a subtractive color mixture principle of three primary colors for printing, so as to realize full-color displaying.

Abstract: Processes of forming Csp2—Csp3 bonds at the allylic carbon of a cyclic allylic compound starting material are disclosed, in which a racemic mixture of a cyclic allylic compound having a leaving group attached to the allylic carbon is reacted with a compound having a nucleophilic carbon atom in the presence of a Rh(I), Pd(II) or Cu(I) pre-catalyst and a chiral ligand. The reaction products containing the newly-formed Csp2—Csp3 bond are generated in high stereoisomeric excess, and may therefore serve as important organic building blocks in the preparation of new agrochemicals and pharmaceuticals.

Abstract: The present system and method allow for preemptive, self-healing computer security. The system includes a user device processor and a PSS server processor. The two processors perform an initial Data Structure & Key Mutation (DSKM) method and an interval DSKM method at a given interval to protect secret information and prevent its exposure by attackers. When a user requests a site or service that is an attractive target for attackers, such as a bank site or monetary transfer service, the processors perform a Man in the Browser attack prevention method. When a packet is received or generated, the processors perform a Deep Protocol and Stateful Inspection and Prevention method to prevent receipt of malicious packets or the loss of sensitive information. Various forensics modules allow accurate forensic examination of the type, scope, and method of attack, as well as real-time protection of cloud-based services.

Abstract: This disclosure describes, generally, a modified form of CD 16, genetically-modified cells that express the modified CD 16, and methods that involve the genetically-modified cells. The modified form of CD 16 can exhibit increased anti-tumor and/or anti- viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.

Abstract: One embodiment is a biochip having an array of biosensors for quantitative determination of protein-protein and/or antibody-antigen interactions. The array comprises at least two biosensors formed on a substrate. The biosensors can be used to detect either the same or different analytes. The biosensors may be acoustical transducers operated in the thickness shear mode of vibration, wherein the density, viscosity, and elasticity at the sensor interface can be ascertained. Additionally, a series of fluidic channels are etched to the same depth as the biosensors. The fluidic channels serve to efficiently deliver the sample to the biosensors. One or more biochips can be housed within an enclosure.

Abstract: This invention relates to a system and methods for determining the placement of an object in a distributed key-value store by mapping the object to nodes in multidimensional hyperspace. A search function supports efficient object retrieval, even when the search query requests multiple objects and specifies them through non-primary keys. In response to a search query, the search is translated into hyperregions in the hyperspace to determine the set of nodes that hold the queried data object. The number of contacted nodes and the number of scanned objects are significantly reduced in comparison to prior art techniques.

Abstract: A method of preventing and/or treating a disease caused by diabetes complications includes administering to a patient in need thereof, an effective amount of thymoquinone or a pharmaceutically acceptable salt thereof, either singly or in combination with a pharmaceutically acceptable carrier, diluent or excipient. The disease can be at least one of retinopathy, nephropathy, neuropathy, and neurological disorder.

Abstract: A three-dimensional electronic, biological, chemical, thermal management, and/or electromechanical apparatus can be configured by depositing one or more layers of a three-dimensional structure on a substrate. Such a three-dimensional structure can include one or more internal cavities using an additive manufacturing system enhanced with a range of secondary embedding processes. The three-dimensional structure can be further configured with structural integrated metal objects spanning the internal cavities (possibly filled with air or even evacuated) of the three-dimensional structure for enhanced electromagnetic properties.

Abstract: Disclosed is a solvent dispensing system that includes a plurality of air-operated double diaphragm pumps, which are adapted to couple to a plurality of solvent supply containers, and coupled to a plurality of dispensing nozzles, wherein each air-operated double diaphragm pump is powered by a separate air supply line carrying pressurized air, and is controlled by a separate air directional control valve. The solvent dispensing system further includes a sealing cap device for coupling a solvent container to a solvent supply line. The sealing cap device is adapted to form a seal around a solvent discharge opening in a solvent container. The sealing cap device has a check valve and breather combination and a fitting for coupling the solvent container to a solvent supply line. Also disclosed is a clamping system for pressing the sealing cap device around the solvent discharge opening in the solvent container.

Abstract: Disclosed are various examples related to ion or particle spectrometry utilizing a monolithic collimator and energy analyzer. In one example, a particle selection device includes a single substrate including a curved channel energy analyzer section and a straight channel collimator section, wherein particles pass through the collimator section and enter the energy analyzer section of the substrate. The channel outlets in the collimator section are aligned with the channel inlets of the energy analyzer section. Electric and/or magnetic fields can be applied across the channels of the energy analyzer for ion or particle discrimination. A particle detector at the outlet of the energy analyzer section can provide indications of detected ions and/or particles.

Abstract: A 3D printing system may print a desired 3D object. A fusible powder may fuse when subjected to a fusing condition. A deposition system may deposit portions of the fusible powder on a substrate. A fusing system may apply the fusing condition to the deposited fusible powder. Inhibitor material may not fuse when subjected to the fusing condition. An insertion system may insert a portion of the inhibitor material between portions of the deposited fusible powder after having been deposited by the deposition system, but before being fused by the fusing system, so as to form a boundary that defines at least a portion of a surface of the desired 3D object.

Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing a PGAM1 mediated condition such as cancer or tumor growth comprising administering an effective amount of PGAM1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, head and neck cancer, and leukemia, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.

Abstract: The methods described herein enable the evaluation of compounds on subjects to assess their therapeutic efficacy or toxic effects. The target of analysis is the underlying biochemical process or processes (i.e., metabolic process) thought to be involved in disease pathogenesis. Molecular flux rates within the one or more biochemical processes serve as biomarkers and are quantitated and compared with the molecular flux rates (i.e., biomarker) from control subjects (i.e., subjects not exposed to the compounds). Any change in the biomarker in the subject relative to the biomarker in the control subject provides the necessary information to evaluate therapeutic efficacy of an administered drug or a toxic effect and to develop the compound further if desired. In one aspect of the invention, stable isotope-labeled substrate molecules are administered to a subject and the label is incorporated into targeted molecules in a manner that reveals molecular flux rates through one or more metabolic pathways of interest.

Abstract: The present disclosure relates to a pre-5th-generation (5G) or 5G communication system to be provided for supporting higher data rates beyond 4th-generation (4G) communication system such as long term evolution (LTE). An apparatus of a base station in a wireless communication system is provided. The apparatus includes at least one processor configured to determine a length of a channel occupancy period and a length of a contention period with respect to a band shared with other system, and a transceiver configured to, when detecting no signal of the other system until a time indicated by a back-off value in the contention period, transmit a signal over the band. A method of a base station in a wireless communication system is provided.

Abstract: The present invention generally to methods of treating subjects suffering from a cardiac condition or having a risk factor for developing a cardiac condition by administering an ELA peptide or fusion protein to a subject in need. The invention relates to fusion proteins of Fc-ELA-32 and Fc-ELA-21 that exhibit improved properties for use as therapeutic agents, e.g. in the treatment of cardiac conditions. In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.

Abstract: Provided herein are materials for the promotion of tissue regeneration, and methods of promoting tissue regeneration and wound healing therewith. In particular, materials displaying laminin-derived peptide sequences that facilitate cell migration into the material, and methods of use thereof, are provided.